Trial Profile
Identification of Tumor Neoantigens During Immune Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Dec 2017 Planned End Date changed from 1 Apr 2021 to 30 Nov 2017.
- 04 Dec 2017 Planned primary completion date changed from 1 Apr 2019 to 30 Nov 2017.
- 04 Dec 2017 Planned initiation date changed from 1 May 2017 to 1 Mar 2017.